Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 213

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Chronic myeloid leukaemia

Not recruiting

Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Farma S.p.A.

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Diffuse large B-cell lymphoma+4

Not recruiting

Study on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tolinapant Lactate
  • Sponsor:Taiho Oncology Inc.

Non-small cell lung cancer

Not recruiting

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Stichting Radboud universitair medisch centrum

Vulval cancer+1

Not recruiting

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Leiden University Medical Center

Metastatic renal cell carcinoma

Not recruiting

Study on Folic Acid for Reducing Mucositis in Patients with Metastatic Kidney Cancer Receiving Targeted Therapy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Region Midtjylland

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Non-small cell lung cancer

Not recruiting

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Novartis Pharma AG

Ovarian cancer

Not recruiting

Title: Study of 5-Aminolevulinic Acid for detecting tumor tissue during surgery in patients with ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Prostate cancer

Not recruiting

Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Unicancer

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.